Skip to main content
Top
Published in: Critical Care 1/2011

Open Access 01-02-2011 | Poster presentation

Comparison of nifekalant and amiodarone for resuscitation after cardiopulmonary arrest due to shock-resistant ventricular fibrillation

Authors: N Harayama, S Nihei, Y Isa, H Arai, T Shinjou, K Nagata, M Ueki, K Aibara, M Kamochi

Published in: Critical Care | Special Issue 1/2011

Login to get access

Excerpt

Nifekalant (NIF) is a pure potassium channel blocker developed in Japan and it has been used widely for treating fatal ventricular tachyarrhythmia since 1999. Because intravenous amiodarone (AMD) was approved in 2007 in Japan, there have been few studies about the comparison of the efficacy of NIF and AMD for resuscitation after cardiopulmonary arrest patients due to shock-resistant ventricular fibrillation. …
Metadata
Title
Comparison of nifekalant and amiodarone for resuscitation after cardiopulmonary arrest due to shock-resistant ventricular fibrillation
Authors
N Harayama
S Nihei
Y Isa
H Arai
T Shinjou
K Nagata
M Ueki
K Aibara
M Kamochi
Publication date
01-02-2011
Publisher
BioMed Central
Published in
Critical Care / Issue Special Issue 1/2011
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc9711

Other articles of this Special Issue 1/2011

Critical Care 1/2011 Go to the issue